U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday.
With this agreement, Johnson & Johnson adds Intra-Cellular Therapies' Caplyta (lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
Intra-Cellular Therapies shares jumped 34.6% to $127.62 on Monday.
Here are some other big stocks recording gains in today's session.
Now Read This:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
